

PATENT **176/60792 (6-11415-868)**

Examiner:

D. Ramirez

Art Unit: 1652

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Mahin D. Maines

Serial No. : 09/606,129

Cnfrm No. : To Be Assigned

Filed : June 28, 2000

For : BILIVERDIN REDUCTASE FRAGMENTS)

AND VARIANTS, AND METHODS OF USING BILIVERDIN REDUCTASE AND SUCH FRAGMENTS AND VARIANTS RECEIVED

AUG 2 6 2002

AMENDMENT TECH CENTER 1600/2900

U.S. Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

Dear Sir:

In response to the March 20, 2002, office action, please amend the aboveidentified patent application as follows:

In the Specification:

Please replace the paragraph at page 2, line 16 to page 3, line 2, with the following amended paragraph.

AI

BVR was previously thought to be simply a house-keeping enzyme found in most mammalian cells in excess of, or in disproportionate levels to, heme oxygenase isozymes (Ewing et al., <u>J. Neurochem.</u> 61:1015-1023 (1993)). Yet it has the above-noted unique and uncommon properties. Examination of the primary structure of human BVR, which recently became available (Maines et al., <u>Eur. J. Biochem.</u> 235:372-381 (1996)), revealed the presence of consensus sequences that are conserved in protein kinases, the most notable one being the Gly.Xaa.Gly¹⁷.Xaa.Xaa.Gly motif near the N terminus of the protein that is found invariably in all kinases (Kamps et al., <u>Nature</u> 310:589-592 (1984); Hunter et al., <u>Ann. Rev. Biochem.</u> 54:897-930 (1985); Schlessinger, <u>Trend. Biochem. Sci.</u> 13:443-447 (1988); Hanks et al., <u>Science</u> 241:42-52 (1988); Yarden et al., <u>Annu. Rev. Biochem.</u> 57:443-478 (1988); Hanks et al., <u>Methods Enzymol.</u> 200:38-62 (1991)). A valine residue is present